Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Maze Therapeutics, Inc. - Common Stock (NQ:MAZE)

39.80 -0.96 (-2.36%)
Streaming Delayed Price Updated: 11:31 AM EST, Dec 10, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Maze Therapeutics, Inc. - Common Stock

< Previous 1 2 Next >
News headline image
Foresite Capital Goes Bullish on Cytokinetics (CYTK), Snapping Up 458K Shares ↗
Foresite Capital Goes Bullish on Cytokinetics (CYTK), Snapping Up 458K Shares 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Maze Therapeutics Reports Third Quarter 2025 Financial Results and Recent Highlights
From Maze Therapeutics, Inc.
Via GlobeNewswire
News headline image
Maze Therapeutics to Present Additional Data Highlighting the Advancement of MZE829 and MZE782 Programs at ASN Kidney Week
From Maze Therapeutics, Inc.
Via GlobeNewswire
News headline image
Maze Therapeutics to Participate in Four Upcoming Investor Conferences
From Maze Therapeutics, Inc.
Via GlobeNewswire
News headline image
Maze Therapeutics Appoints Industry Veteran Hervé Hoppenot as Chairman of the Board of Directors
Mr. Hoppenot, a seasoned biotech leader who has driven transformative therapies to market, joins Maze to fuel its evolution into a leading clinical-stage biotech 
From Maze Therapeutics, Inc.
Via GlobeNewswire
News headline image
Biotech Breakouts: 3 Stocks With Massive Upside Potential ↗
Biotech stocks are highly volatile; however, these biotech stocks have key trial results this fall that could spark sharp moves and long-term growth potential 
Via MarketBeat
News headline image
What's going on in today's session ↗
Curious to know what's happening on the US markets one hour before the close of the markets on Thursday? Join us as we explore the top gainers and losers in today's session. 
Via Chartmill
News headline image
Maze Shares Jump As Investors Bet Big On Experimental Treatment's Potential ↗
Maze's MZE782 showed strong Phase 1 results, supporting once- or twice-daily dosing with increased amino acid excretion and no serious side effects. 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Thursday's Intraday Session ↗
 
Via Benzinga
News headline image
Which stocks are moving on Thursday? ↗
Looking for insights into the US markets in the middle of the day on Thursday? Delve into the top gainers and losers of today's session and gain valuable market intelligence. 
Via Chartmill
News headline image
Maze Therapeutics, Opendoor Technologies, Oxford Industries, VNET Group And Other Big Stocks Moving Higher On Thursday ↗
 
Via Benzinga
News headline image
Thursday's session: gap up and gap down stocks ↗
Let's have a look at the gap up and gap down stocks in today's session. 
Via Chartmill
News headline image
Why Maze Therapeutics, Up 51%, Was Shocked By Its Own Test Results ↗
Shares catapulted Thursday after its experimental treatment for a rare, genetic disease blew past expectations. 
Via Investor's Business Daily
News headline image
Discover the top movers in Thursday's pre-market session. ↗
As we await the opening of the US market on Thursday, let's delve into the pre-market session and discover the top gainers and losers shaping the early market sentiment. 
Via Chartmill
News headline image
12 Health Care Stocks Moving In Thursday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Maze Therapeutics Announces Oversubscribed $150.0 Million Private Placement
From Maze Therapeutics, Inc.
Via GlobeNewswire
News headline image
Maze Therapeutics Announces Positive First-in-Human Results from Phase 1 Trial of MZE782, Establishing Proof of Mechanism for a Potent, Oral SLC6A19 Inhibitor with Potential to Treat Phenylketonuria (PKU) and Chronic Kidney Disease (CKD)
From Maze Therapeutics, Inc.
Via GlobeNewswire
News headline image
Maze Therapeutics Appoints Misbah Tahir as Chief Financial Officer
From Maze Therapeutics, Inc.
Via GlobeNewswire
News headline image
Maze Therapeutics Inc (NASDAQ:MAZE) Reports Narrower Q2 2025 Loss, Extends Cash Runway to 2027 ↗
Maze Therapeutics reports Q2 2025 earnings with a narrower loss than expected, extends cash runway to 2027, and advances kidney disease clinical trials. 
Via Chartmill
News headline image
Maze Therapeutics Reports Second Quarter 2025 Financial Results and Recent Highlights
From Maze Therapeutics, Inc.
Via GlobeNewswire
News headline image
12 Health Care Stocks Moving In Monday's After-Market Session ↗
 
Via Benzinga
News headline image
This Celsius Holdings Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday ↗
 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Wednesday's After-Market Session ↗
 
Via Benzinga
News headline image
Maze Therapeutics to Participate in Two Upcoming Investor Conferences
From Maze Therapeutics, Inc.
Via GlobeNewswire
News headline image
Maze Therapeutics to Participate in the Jefferies 2025 Global Healthcare Conference
From Maze Therapeutics, Inc.
Via GlobeNewswire
News headline image
12 Health Care Stocks Moving In Wednesday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Maze Therapeutics Reports First Quarter 2025 Financial Results and Reiterates Upcoming Milestones
From Maze Therapeutics, Inc.
Via GlobeNewswire
News headline image
Maze Therapeutics to Participate in the 3rd Annual H.C. Wainwright BioConnect Investor Conference
From Maze Therapeutics, Inc.
Via GlobeNewswire
News headline image
12 Health Care Stocks Moving In Friday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Booz Allen Hamilton, Movado Group And Other Big Stocks Moving Lower In Friday's Pre-Market Session ↗
 
Via Benzinga
< Previous 1 2 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.